AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01622556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 35 mg/m2 IV/day x 5 days
Study NCT01622556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: .8 mg/kg IV Q6h x 8 doses
Study NCT01622556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 1.5 mg/kg/day x 3 days
Study NCT01622556 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 150 cGy for 2 days
Study NCT01622556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood
Description: Two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient.
Study NCT03893578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral valve-in-valve
Description: The Synecor Conveyor System shall be used to position the Edwards SAPIEN 3 valve at the mitral location.
Study NCT02276417 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: Blood will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Blood will also be collected at the one year appointment.
Study NCT02276417 — intervention group
Intervention type: OTHER
Intervention: Urine collection
Description: Urine will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Urine will also be collected at the one year appointment.
Study NCT02276417 — intervention group
Intervention type: OTHER
Intervention: Bioimpedance Analysis
Description: The bioimpedance analysis will be performed at baseline, day 14 or discharge from hospitalization, month 3, month 6, and month 12.
Study NCT02276417 — intervention group
Intervention type: OTHER
Intervention: Cognitive Function Tests
Description: Cognitive function tests will be administered at 3, 6 and 12 months.
Study NCT02276417 — intervention group
Intervention type: OTHER
Intervention: Quality-of-life Questionnaires
Description: Quality-of-life questionnaires will be administered at baseline, 3, 6 and 12 months.
Study NCT02276417 — intervention group
Intervention type: OTHER
Intervention: Physical Function Tests
Description: Physical function tests will be administered at baseline, day 14 or discharge from hospital 3, 6 and 12 months.
Study NCT02276417 — intervention group
Intervention type: OTHER
Intervention: Blood Collection
Description: The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
Study NCT04722562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
Study NCT02321852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triflusal
Description: Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
Study NCT03775486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
Study NCT03775486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Olaparib
Description: Matching tablet
Study NCT03775486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
Study NCT03775486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel+carboplatin
Description: Standard of Care chemotherapy (squamous and non-squamous patients)
Study NCT03775486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+carboplatin
Description: Standard of Care chemotherapy (squamous patients only)
Study NCT03775486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed+carboplatin
Description: Standard of Care chemotherapy (non-squamous patients only)
Study NCT03775486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+cisplatin
Description: Standard of Care chemotherapy (squamous patients only)
Study NCT03775486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed+cisplatin
Description: Standard of Care chemotherapy (non-squamous patients only)
Study NCT02846272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Observation
Description: Observation of MRI changes in subjects
Study NCT00784940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg, orally, once daily
Study NCT00784940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg, orally, once daily
Study NCT02271438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive a single oral dose of 12 capsules (12\*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6\*140 mg capsules) of ibrutinib in Treatment B.
Study NCT02271438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.
Study NCT02271438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib-matching placebo
Description: Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.
Study NCT02271438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-matching placebo
Description: Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.
Study NCT00631839 — intervention group
Intervention type: RADIATION
Intervention: Thoracic 3-D Conformal Radiotherapy
Description: Thoracic RT tailored for each patient, about 60Gy (NSCLC) or 55Gy (SCLC) with photon energies >=6MV.
Study NCT04002843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paraclinical evaluation of single fibre
Description: ENMG 5 channel Digital EMG, NCS and EP System, Neurosoft, Skybox. Amplification of the EMG signal BF 500 Hz, HF 3kHz, mains filter at 50 Hz. Acquisition at 2 ms at 100 µv, parameters can be modified. The single-use needle electrode (Neuroline Concentric, Neurology Needle Electrode; 25x0.30 mm(1''x30G)) of reference inserted into one elbow flexor muscle (biceps brachialis, anterior brachialis) on the parietal side with location of the ground reference. The paroetic arm will be supported by the evaluator in order to generate a minimal tone, necessary for the occurrence of potential actions of two muscle fibres present within the same motor unit.
Study NCT04002843 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: paraclinical evaluation of single fibre
Description: ENMG 5 channel Digital EMG, NCS and EP System, Neurosoft, Skybox. Amplification of the EMG signal BF 500 Hz, HF 3kHz, mains filter at 50 Hz. Acquisition at 2 ms at 100 µv, parameters can be modified. The single-use needle electrode (Neuroline Concentric, Neurology Needle Electrode; 25x0.30 mm(1''x30G)) of reference inserted into one elbow flexor muscle (biceps brachialis, anterior brachialis) on the parietal side with location of the ground reference. The paroetic arm will be supported by the evaluator in order to generate a minimal tone, necessary for the occurrence of potential actions of two muscle fibres present within the same motor unit.
Study NCT02321852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily oral administration of placebo mannitol for 7 days
Study NCT03802552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Description: oral one-time dose of cefadroxil
Study NCT03802552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: oral one-time dose of cephalexin
Study NCT00945646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FST-201 (dexamethasone 0.1%) Otic Suspension
Description: Instill four drops times two times a day.
Study NCT00945646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Instill four times two times a day
Study NCT02914834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Standardized acupuncture treatment administered for 30 minutes each session
Study NCT02914834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-pain related video health education
Description: Attention control group will watch health education videos the equivalent of 10 hours from randomization up to study completion.
Study NCT01213381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib (SAR240550 - BSI-201)
Description: Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous
Study NCT01213381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous
Study NCT01213381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous
Study NCT04847024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: 40 mg IV
Study NCT04847024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: 50 mg IV
Study NCT03794895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler
Description: Doing doppler for women having IUCD associated menorrhagia
Study NCT03330509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARK intervention
Description: An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
Study NCT02479841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self management program
Study NCT03530891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer guided lag screw fixation
Description: Under general anaesthesia: Patient specific pre operative prefabricated surgical guide will be used intra operative for open reduction and internal fixation for anterior mandibular fracture using lag screws.
Study NCT03530891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional lag screw fixation
Description: Under general anaesthesia: Open reduction and internal fixation for anterior mandibular fracture utilising lag screws.
Study NCT03353376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group care with Empowerment model
Description: Patients with type 2 and type 1 diabetes were followed in a tertiary outpatient clinic with group appointment
Study NCT03353376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group care with Empowerment model
Description: Patients with type 2 and type 1 diabetes were followed in a tertiary outpatient clinic with group appointment
Study NCT02541344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dose 1 of IQP-VV-102
Description: Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.
Study NCT02541344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dose 2 of IQP-VV-102
Description: Dose 2 (D2) group will take 4 tablets with active ingredients.
Study NCT02541344 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will take 4 placebo tablets.~The placebo is designed to be identical to IQP-VV-102.
Study NCT00746369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMARA HIV Prevention Intervention
Description: Three individual sessions- behavioral intervention for incarcerated female adolescents.
Study NCT02704767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China
Study NCT02704767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Study NCT02704767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tarceva
Study NCT02704767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03398096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac shock wave therapy
Description: Ultrasound guided cardiac shock wave therapy (CSWT) is a new treatment method offering an alternative to revascularization by stimulating angiogenesis. Subsequent clinical trials showed that CSWT could reduce symptoms of myocardial ischemia and improve cardiac function in patients with severe coronary artery disease.
Study NCT02765737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dehydrated Human Amnion/Chorion Membrane
Description: Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).
Study NCT02765737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Ag
Study NCT02173782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat ® high dose
Study NCT02173782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat ® low dose
Study NCT02173782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® MDI
Study NCT02173782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00244049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling
Description: Physicians discussed high-risk/binge drinking with college-aged individuals in a health care setting.
Study NCT00244049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Physicians discussed effects of high-risk/binge drinking with college-aged individuals in a health care setting.
Study NCT00892021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSA-789
Study NCT00892021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03656341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Feet 4 Life
Description: 2 Feet 4 Life consists of four weekly group intervention sessions of one hour each. 2 Feet 4 Life includes self-management teaching, interactive lecture, and group activities, including instruction and demonstration of routine foot care. The program includes education regarding appropriate footwear and how to find it, evidenced based practices on hygiene, skin care and self-care of the lower extremities, nail trimming and filing, and care of common foot problems.
Study NCT04182919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phlai
Description: Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks
Study NCT04182919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks
Study NCT04182919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks
Study NCT01976000 — intervention group
Intervention type: PROCEDURE
Intervention: multi-slice Computed Tomography angiography and three-dimensional reconstruction software
Study NCT04270812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C)
Description: TranS-C adopts a modular approach to reversing the psychosocial, behavioral, and cognitive processes maintaining sleep problems via 4 cross-cutting modules (introduced in the first session and included in every session thereafter), 4 core modules and 7 optional modules. TranS-C typically involves 6-8 individual, weekly 50-minute sessions.
Study NCT01958905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine fixed combination
Study NCT01499485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Daily morning ABGA:~* If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of acetazolamide 500 mg .~* If actual bicarbonate > 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of acetazolamide 500 mg.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day.
Study NCT01499485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily morning ABGA:~* If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of placebo.~* If actual bicarbonate > 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of placebo.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day.
Study NCT05116436 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: It will test the presence or absence of genetic mutations found in other cohorts in previous studies.
Study NCT05116436 — intervention group
Intervention type: PROCEDURE
Intervention: Spine X-ray
Description: To determine the scoliosis
Study NCT00758446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLX-028914
Description: 50 mg capsules, p.o, daily, 14 days
Study NCT00758446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLX-028914
Description: 15 mg capsules, p.o, daily, 14 days
Study NCT01134952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate to sirolimus switch
Description: Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
Study NCT00758446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules, p.o, daily, 14 days
Study NCT04502732 — intervention group
Intervention type: OTHER
Intervention: NSSM and GEBT
Description: The time to half gastric emptying (T1/2) will be assessed via Gastric Emptying Breath Tests (GEBT) and Nuclear Scintigraphy of a Solid Meal (NSSM) at baseline, 2 months, and 6 months. This data will be collected from seven adult subjects, with obesity, who have recently received Endoscopic Bariatric and Metabolic Therapy.
Study NCT00685516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: green tea
Description: 6 cups of green tea daily for 2-8 weeks
Study NCT00685516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 cups of water daily for 2-8 weeks
Study NCT00685516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: decaffeinated black tea
Description: 6 cups of decaffeinated black tea daily for 2-8 weeks
Study NCT04122261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the MicroHand S endoscopic instrument control system
Description: Using the MicroHand S endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
Study NCT04122261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the da Vinci endoscopic instrument control system
Description: Using the da Vinci endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
Study NCT01792739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei variety rhamnosus granules
Description: Lactobacillus casei variety rhamnosus granules~: 3 gram per day (1g-1g-1g, 3 times per day)
Study NCT01792739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules~: 3 gram per day (1g-1g-1g, 3 times per day)
Study NCT05410678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renal stent
Description: renal stent implantation in ectatic/aneurysmatic coronary arteries
Study NCT05410678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renal stent
Description: renal stent implantation in ectatic/aneurysmatic coronary arteries
Study NCT00109863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2 fusion protein
Study NCT03471052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Description: Ablation using the Barrx RFA System is a new technique for field ablation in the oesophagus. It has been used for eradication of diseased epithelium of all three subclasses of Barrett's oesophagus (non-dysplastic Intestinal metaplasia (IM), Low grade dysplasia (LGD) and High grade dysplasia (HGD). The BarrxTM RFA System uses ultra short pulse RF energy delivering 40Watts/cm2 power density and 12Joule/cm2 energy density, and affects the mucosa whilst preserving the submucosa.~Clinical trials have suggested that it is safe and effective for treating non-dysplastic IM, LGD and HGD in Barrett's oesophagus . Long term data show the effect to be durable over 5 years.
Study NCT03384589 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Vaccine against pneumococcal disease
Study NCT03384589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Vaccine against pneumococcal disease